Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.4M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
25.2M
-
Shares change
-
+573K
-
Total reported value, excl. options
-
$429M
-
Value change
-
+$10.8M
-
Number of buys
-
42
-
Number of sells
-
-18
-
Price
-
$17.05
Significant Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS) as of Q2 2023
77 filings reported holding MLYS - Mineralys Therapeutics, Inc. - Common Stock as of Q2 2023.
Mineralys Therapeutics, Inc. - Common Stock (MLYS) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.2M shares
of 77.4M outstanding shares and own 32.54% of the company stock.
Largest 10 shareholders include Samsara BioCapital, LLC (4.52M shares), RA CAPITAL MANAGEMENT, L.P. (3.18M shares), ADAMS STREET PARTNERS LLC (2.42M shares), SR ONE CAPITAL MANAGEMENT, LP (1.79M shares), Rock Springs Capital Management LP (1.17M shares), VANGUARD GROUP INC (926K shares), RTW INVESTMENTS, LP (922K shares), BlackRock Inc. (884K shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (837K shares), and Avidity Partners Management LP (767K shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.